Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Income from Continuing Operations (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Income from Continuing Operations for 17 consecutive years, with 1887434.0 as the latest value for Q1 2026.

  • Quarterly Income from Continuing Operations fell 167.89% to 1887434.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 4499599.0 through Jan 2026, up 1.51% year-over-year, with the annual reading at 2962301.0 for FY2025, 42.16% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 1887434.0 at PharmaCyte Biotech, down from 1169664.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 180346.0 in Q2 2023, with the low at 2419118.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 1089646.82, with a median of 917094.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations skyrocketed 87.31% in 2023, then tumbled 1241.38% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 1879449.0 in 2022, then soared by 72.58% to 515339.0 in 2023, then crashed by 40.39% to 723498.0 in 2024, then crashed by 61.67% to 1169664.0 in 2025, then crashed by 61.37% to 1887434.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 1887434.0, 1169664.0, and 630512.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.